Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,deferredLongTermLiab,otherAssets,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,investments,otherCashflowsFromInvestingActivities,dividendsPaid,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,DMP.DE,-203604000.0,53840000,,,49024000,2550000,36312000,40717000,133411000,49439000,49439000,31828000,-2459000,,,,12778000,215706000,166267000,82295000,-415000,,36246000,36312000,295583000.0,915915000.0,358325000.0,62787000.0,1276790000.0,53840000.0,17643000.0,213393000.0,187280000.0,266346000.0,91092000.0,145745000.0,148848000.0,26265000.0,91092000.0,199943000.0,454190000.0,60728000.0,3360000.0,71333000.0,579787000.0,216109000.0,59795000.0,,,0.0,-9378000.0,-1727000.0,-3422000.0,-12752000.0,25445000.0,432000.0,37813000.0,11291000.0,-1695000.0,2962000.0,-9508000.0,,,,305342000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,DERMAPHARM HLDG INH O.N.,False,False,GER,79.1,1630504322,0.5,79.1,79.35,78.55,17062,REGULAR,0,2,0.6361323,78.55 - 79.35,78.6,79.0,79.1,0,0,finmb_549517766,Dermapharm Holding SE,XETRA,EUR,38891,52502,38.315,0.93943846,40.785 - 79.35,-0.25,-0.0031505986,40.785,79.35,1617101940,1617101940,1617101940,0.88,49.748425,0.011195929,1.59,5.98,70.30278,8.797218,0.12513329,67.70366,11.396339,0.16832678,4171583744,13.227425,15,Europe/Berlin,CEST,7200000,1.11,,,79.35,40.78,70.3,67.7,38.89k,52.5k,53.84M,,18.82M,65.05%,17.44%,,,,,,0.88,1.28%,0.88,1.12%,,45.45%,,"Jun 24, 2021",,,"Dec 31, 2020","Mar 31, 2021",11.53%,19.18%,8.40%,28.38%,828.19M,15.32,10.10%,453.89M,175.22M,95.47M,1.59,36.20%,149.1M,2.77,606.05M,167.94,3.05,5.98,138.89M,65.34M,Value,82031,Healthcare,2311,6,7,"Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics primarily under the Dekristol, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; food supplements under the HÃ¼bner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. Dermapharm Holding SE has partnership with CORAT Therapeutics GmbH for the development of COR-101. The company was founded in 1991 and is headquartered in GrÃ¼nwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.",GrÃ¼nwald,49 89 6 41 86 0,1,1625097600,10,Germany,http://www.dermapharm.de,86400,10,Lil-Dagover-Ring 7,49 89 6 41 86 130,Drug Manufacturers—Specialty & Generic
t-1,DMP.DE,-179541000.0,53840000,,,34994000,2616000,24539000,37554000,123526000,51560000,51560000,22539000,-1415000,,,,10715000,220998000,169438000,97472000,-16566000,,24279000,24539000,235239000.0,899814000.0,321966000.0,17056000.0,1224396000.0,53840000.0,7825000.0,177082000.0,186183000.0,266268000.0,91044000.0,120301000.0,132872000.0,22205000.0,91044000.0,199619000.0,400052000.0,59838000.0,1519000.0,62723000.0,570483000.0,205726000.0,50370000.0,62103000.0,63380000.0,0.0,-17791000.0,-1760000.0,-19538000.0,23625000.0,27055000.0,-227000.0,64609000.0,-13553000.0,-17778000.0,5325000.0,-13101000.0,100000.0,1480000.0,,267180000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,DERMAPHARM HLDG INH O.N.,False,False,GER,79.1,1630504322,0.5,79.1,79.35,78.55,17062,REGULAR,0,2,0.6361323,78.55 - 79.35,78.6,79.0,79.1,0,0,finmb_549517766,Dermapharm Holding SE,XETRA,EUR,38891,52502,38.315,0.93943846,40.785 - 79.35,-0.25,-0.0031505986,40.785,79.35,1617101940,1617101940,1617101940,0.88,49.748425,0.011195929,1.59,5.98,70.30278,8.797218,0.12513329,67.70366,11.396339,0.16832678,4171583744,13.227425,15,Europe/Berlin,CEST,7200000,1.11,,,79.35,40.78,70.3,67.7,38.89k,52.5k,53.84M,,18.82M,65.05%,17.44%,,,,,,0.88,1.28%,0.88,1.12%,,45.45%,,"Jun 24, 2021",,,"Dec 31, 2020","Mar 31, 2021",11.53%,19.18%,8.40%,28.38%,828.19M,15.32,10.10%,453.89M,175.22M,95.47M,1.59,36.20%,149.1M,2.77,606.05M,167.94,3.05,5.98,138.89M,65.34M,Value,82031,Healthcare,2311,6,7,"Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics primarily under the Dekristol, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; food supplements under the HÃ¼bner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. Dermapharm Holding SE has partnership with CORAT Therapeutics GmbH for the development of COR-101. The company was founded in 1991 and is headquartered in GrÃ¼nwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.",GrÃ¼nwald,49 89 6 41 86 0,1,1625097600,10,Germany,http://www.dermapharm.de,86400,10,Lil-Dagover-Ring 7,49 89 6 41 86 130,Drug Manufacturers—Specialty & Generic
t-2,DMP.DE,-252802000.0,53840000,,,31628000,6201000,22652000,38850000,115845000,32389000,32389000,32821000,-3003000,,,,9061000,202367000,169978000,86522000,-761000,,22567000,22652000,297440000.0,917811000.0,297251000.0,64984000.0,1221263000.0,53840000.0,10799000.0,158688000.0,182120000.0,252613000.0,84723000.0,105493000.0,134239000.0,19470000.0,84723000.0,196495000.0,412038000.0,62677000.0,4529000.0,65518000.0,601452000.0,225699000.0,49785000.0,,,0.0,-12343000.0,-1804000.0,-3371000.0,-11192000.0,9587000.0,-264000.0,25565000.0,11566000.0,-1567000.0,2539000.0,-12693000.0,100000.0,-1000.0,,277799000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,DERMAPHARM HLDG INH O.N.,False,False,GER,79.1,1630504322,0.5,79.1,79.35,78.55,17062,REGULAR,0,2,0.6361323,78.55 - 79.35,78.6,79.0,79.1,0,0,finmb_549517766,Dermapharm Holding SE,XETRA,EUR,38891,52502,38.315,0.93943846,40.785 - 79.35,-0.25,-0.0031505986,40.785,79.35,1617101940,1617101940,1617101940,0.88,49.748425,0.011195929,1.59,5.98,70.30278,8.797218,0.12513329,67.70366,11.396339,0.16832678,4171583744,13.227425,15,Europe/Berlin,CEST,7200000,1.11,,,79.35,40.78,70.3,67.7,38.89k,52.5k,53.84M,,18.82M,65.05%,17.44%,,,,,,0.88,1.28%,0.88,1.12%,,45.45%,,"Jun 24, 2021",,,"Dec 31, 2020","Mar 31, 2021",11.53%,19.18%,8.40%,28.38%,828.19M,15.32,10.10%,453.89M,175.22M,95.47M,1.59,36.20%,149.1M,2.77,606.05M,167.94,3.05,5.98,138.89M,65.34M,Value,82031,Healthcare,2311,6,7,"Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics primarily under the Dekristol, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; food supplements under the HÃ¼bner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. Dermapharm Holding SE has partnership with CORAT Therapeutics GmbH for the development of COR-101. The company was founded in 1991 and is headquartered in GrÃ¼nwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.",GrÃ¼nwald,49 89 6 41 86 0,1,1625097600,10,Germany,http://www.dermapharm.de,86400,10,Lil-Dagover-Ring 7,49 89 6 41 86 130,Drug Manufacturers—Specialty & Generic
t-3,DMP.DE,-272662000.0,53840000,,,21869000,6286000,11971000,43024000,108253000,23780000,23780000,29449000,-2782000,,,,9606000,189114000,165334000,80861000,-1911000,,12263000,11971000,296940000.0,920987000.0,275002000.0,62239000.0,1202275000.0,53840000.0,13866000.0,136036000.0,181625000.0,250724000.0,85126000.0,97695000.0,137102000.0,3124000.0,85126000.0,195590000.0,395995000.0,63026000.0,4053000.0,67040000.0,591159000.0,213341000.0,53864000.0,,,0.0,-69715000.0,55717000.0,10874000.0,-15759000.0,-47274000.0,-162000.0,10902000.0,11295000.0,-1771000.0,3395000.0,-7092000.0,100000.0,1000.0,-43072000.0,258893000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,DERMAPHARM HLDG INH O.N.,False,False,GER,79.1,1630504322,0.5,79.1,79.35,78.55,17062,REGULAR,0,2,0.6361323,78.55 - 79.35,78.6,79.0,79.1,0,0,finmb_549517766,Dermapharm Holding SE,XETRA,EUR,38891,52502,38.315,0.93943846,40.785 - 79.35,-0.25,-0.0031505986,40.785,79.35,1617101940,1617101940,1617101940,0.88,49.748425,0.011195929,1.59,5.98,70.30278,8.797218,0.12513329,67.70366,11.396339,0.16832678,4171583744,13.227425,15,Europe/Berlin,CEST,7200000,1.11,,,79.35,40.78,70.3,67.7,38.89k,52.5k,53.84M,,18.82M,65.05%,17.44%,,,,,,0.88,1.28%,0.88,1.12%,,45.45%,,"Jun 24, 2021",,,"Dec 31, 2020","Mar 31, 2021",11.53%,19.18%,8.40%,28.38%,828.19M,15.32,10.10%,453.89M,175.22M,95.47M,1.59,36.20%,149.1M,2.77,606.05M,167.94,3.05,5.98,138.89M,65.34M,Value,82031,Healthcare,2311,6,7,"Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics primarily under the Dekristol, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; food supplements under the HÃ¼bner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. Dermapharm Holding SE has partnership with CORAT Therapeutics GmbH for the development of COR-101. The company was founded in 1991 and is headquartered in GrÃ¼nwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.",GrÃ¼nwald,49 89 6 41 86 0,1,1625097600,10,Germany,http://www.dermapharm.de,86400,10,Lil-Dagover-Ring 7,49 89 6 41 86 130,Drug Manufacturers—Specialty & Generic
